These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 25839104)

  • 1. Induction of CD8(+) T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine.
    Pearson FE; O'Mahony C; Moore AC; Hill AV
    Vaccine; 2015 Jun; 33(28):3248-55. PubMed ID: 25839104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microneedle array design determines the induction of protective memory CD8+ T cell responses induced by a recombinant live malaria vaccine in mice.
    Carey JB; Pearson FE; Vrdoljak A; McGrath MG; Crean AM; Walsh PT; Doody T; O'Mahony C; Hill AV; Moore AC
    PLoS One; 2011; 6(7):e22442. PubMed ID: 21799855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
    Ogwang C; Afolabi M; Kimani D; Jagne YJ; Sheehy SH; Bliss CM; Duncan CJ; Collins KA; Garcia Knight MA; Kimani E; Anagnostou NA; Berrie E; Moyle S; Gilbert SC; Spencer AJ; Soipei P; Mueller J; Okebe J; Colloca S; Cortese R; Viebig NK; Roberts R; Gantlett K; Lawrie AM; Nicosia A; Imoukhuede EB; Bejon P; Urban BC; Flanagan KL; Ewer KJ; Chilengi R; Hill AV; Bojang K
    PLoS One; 2013; 8(3):e57726. PubMed ID: 23526949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP.
    Bliss CM; Bowyer G; Anagnostou NA; Havelock T; Snudden CM; Davies H; de Cassan SC; Grobbelaar A; Lawrie AM; Venkatraman N; Poulton ID; Roberts R; Mange PB; Choudhary P; Faust SN; Colloca S; Gilbert SC; Nicosia A; Hill AVS; Ewer KJ
    Sci Rep; 2018 Feb; 8(1):3390. PubMed ID: 29467399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
    Sklar MJ; Maiolatesi S; Patterson N; Sedegah M; Limbach K; Teneza-Mora N; Chuang I; Hollis-Perry KM; Banania JG; Guzman I; Ganeshan H; Reyes S; Hollingdale MR; Wong M; Lindstrom A; Reyes A; Alcorta Y; Garver L; Bankard K; Belmonte A; Belmonte M; Huang J; Gowda K; Inoue S; Velasco R; Bergmann-Leitner E; Hutter J; Lee T; Adams N; Chaudhury S; Hunt D; Tamminga C; Berrie E; Bellamy D; Bittaye M; Ewer K; Diggs C; Soisson LA; Lawrie A; Hill A; Richie TL; Villasante E; Epstein JE; Duplessis CA
    PLoS One; 2021; 16(9):e0256980. PubMed ID: 34495988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.
    Hodgson SH; Ewer KJ; Bliss CM; Edwards NJ; Rampling T; Anagnostou NA; de Barra E; Havelock T; Bowyer G; Poulton ID; de Cassan S; Longley R; Illingworth JJ; Douglas AD; Mange PB; Collins KA; Roberts R; Gerry S; Berrie E; Moyle S; Colloca S; Cortese R; Sinden RE; Gilbert SC; Bejon P; Lawrie AM; Nicosia A; Faust SN; Hill AV
    J Infect Dis; 2015 Apr; 211(7):1076-86. PubMed ID: 25336730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
    Mensah VA; Gueye A; Ndiaye M; Edwards NJ; Wright D; Anagnostou NA; Syll M; Ndaw A; Abiola A; Bliss C; Gomis JF; Petersen I; Ogwang C; Dieye T; Viebig NK; Lawrie AM; Roberts R; Nicosia A; Faye B; Gaye O; Leroy O; Imoukhuede EB; Ewer KJ; Bejon P; Hill AV; Cisse B;
    PLoS One; 2016; 11(12):e0167951. PubMed ID: 27978537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei.
    Reyes-Sandoval A; Sridhar S; Berthoud T; Moore AC; Harty JT; Gilbert SC; Gao G; Ertl HC; Wilson JC; Hill AV
    Eur J Immunol; 2008 Mar; 38(3):732-41. PubMed ID: 18266272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
    Sheehy SH; Duncan CJ; Elias SC; Biswas S; Collins KA; O'Hara GA; Halstead FD; Ewer KJ; Mahungu T; Spencer AJ; Miura K; Poulton ID; Dicks MD; Edwards NJ; Berrie E; Moyle S; Colloca S; Cortese R; Gantlett K; Long CA; Lawrie AM; Gilbert SC; Doherty T; Nicosia A; Hill AV; Draper SJ
    PLoS One; 2012; 7(2):e31208. PubMed ID: 22363582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine.
    Alves E; Salman AM; Leoratti F; Lopez-Camacho C; Viveros-Sandoval ME; Lall A; El-Turabi A; Bachmann MF; Hill AV; Janse CJ; Khan SM; Reyes-Sandoval A
    Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28179403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children.
    Tiono AB; Nébié I; Anagnostou N; Coulibaly AS; Bowyer G; Lam E; Bougouma EC; Ouedraogo A; Yaro JBB; Barry A; Roberts R; Rampling T; Bliss C; Hodgson S; Lawrie A; Ouedraogo A; Imoukhuede EB; Ewer KJ; Viebig NK; Diarra A; Leroy O; Bejon P; Hill AVS; Sirima SB
    PLoS One; 2018; 13(12):e0208328. PubMed ID: 30540808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine.
    Longley RJ; Halbroth BR; Salman AM; Ewer KJ; Hodgson SH; Janse CJ; Khan SM; Hill AVS; Spencer AJ
    Infect Immun; 2017 Mar; 85(3):. PubMed ID: 28031267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites.
    Bauza K; Malinauskas T; Pfander C; Anar B; Jones EY; Billker O; Hill AV; Reyes-Sandoval A
    Infect Immun; 2014 Mar; 82(3):1277-86. PubMed ID: 24379295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route.
    Carey JB; Vrdoljak A; O'Mahony C; Hill AV; Draper SJ; Moore AC
    Sci Rep; 2014 Aug; 4():6154. PubMed ID: 25142082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice.
    Pearson FE; McNeilly CL; Crichton ML; Primiero CA; Yukiko SR; Fernando GJ; Chen X; Gilbert SC; Hill AV; Kendall MA
    PLoS One; 2013; 8(7):e67888. PubMed ID: 23874462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates.
    Capone S; Reyes-Sandoval A; Naddeo M; Siani L; Ammendola V; Rollier CS; Nicosia A; Colloca S; Cortese R; Folgori A; Hill AV
    Vaccine; 2010 Dec; 29(2):256-65. PubMed ID: 21029806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus.
    Anderson RJ; Hannan CM; Gilbert SC; Laidlaw SM; Sheu EG; Korten S; Sinden R; Butcher GA; Skinner MA; Hill AV
    J Immunol; 2004 Mar; 172(5):3094-100. PubMed ID: 14978115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prime-boost immunization regimen based on a simian adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice.
    Fonseca JA; McCaffery JN; Kashentseva E; Singh B; Dmitriev IP; Curiel DT; Moreno A
    Vaccine; 2017 May; 35(24):3239-3248. PubMed ID: 28483199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity.
    Epstein JE; Tewari K; Lyke KE; Sim BK; Billingsley PF; Laurens MB; Gunasekera A; Chakravarty S; James ER; Sedegah M; Richman A; Velmurugan S; Reyes S; Li M; Tucker K; Ahumada A; Ruben AJ; Li T; Stafford R; Eappen AG; Tamminga C; Bennett JW; Ockenhouse CF; Murphy JR; Komisar J; Thomas N; Loyevsky M; Birkett A; Plowe CV; Loucq C; Edelman R; Richie TL; Seder RA; Hoffman SL
    Science; 2011 Oct; 334(6055):475-80. PubMed ID: 21903775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prime-boost vectored malaria vaccines: progress and prospects.
    Hill AV; Reyes-Sandoval A; O'Hara G; Ewer K; Lawrie A; Goodman A; Nicosia A; Folgori A; Colloca S; Cortese R; Gilbert SC; Draper SJ
    Hum Vaccin; 2010 Jan; 6(1):78-83. PubMed ID: 20061802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.